These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24804341)

  • 1. The new strategy for statins: should you be taking one? Guidelines for taking cholesterol-lowering drugs now target overall risk rather than cholesterol values.
    Harv Heart Lett; 2014 Feb; 24(6):1, 7. PubMed ID: 24804341
    [No Abstract]   [Full Text] [Related]  

  • 2. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Statins and the risk of diabetes].
    Simonyi G
    Orv Hetil; 2013 Oct; 154(43):1691-5. PubMed ID: 24140507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy.
    Rapezzi C; Biagini E; Bellis P; Cafiero M; Velussi M; Ceriello A; Cooke RM; Schweiger C;
    J Cardiovasc Med (Hagerstown); 2008 Sep; 9(9):878-87. PubMed ID: 18695423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical practice guidelines for the management of dyslipidemia in chronic kidney disease].
    Shoji T
    Nihon Jinzo Gakkai Shi; 2013; 55(7):1267-75. PubMed ID: 24288962
    [No Abstract]   [Full Text] [Related]  

  • 7. [Are therapeutic LDL goals justified? Controversies between the European and American guidelines].
    Bertomeu-Martínez V
    Medwave; 2016 Dec; 16(Suppl4):e6825. PubMed ID: 28055995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention].
    Olsson AG
    Lakartidningen; 2011 Nov 23-29; 108(47):2442-3. PubMed ID: 22468387
    [No Abstract]   [Full Text] [Related]  

  • 9. [Adherence to statins: updates and practical proposals].
    Bauwens M; Schneider MP; Nanchen D
    Rev Med Suisse; 2016 Mar; 12(508):445-8, 450. PubMed ID: 27089601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer, lower, better? Lipid drugs and cardiovascular disease--the continuing story.
    Wierzbicki AS
    Int J Clin Pract; 2007 Jul; 61(7):1064-7. PubMed ID: 17577288
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of dyslipidemia in 2014: European versus American guidelines].
    Radermecker RP
    Rev Med Suisse; 2014 Aug; 10(439):1534-7. PubMed ID: 25272669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk].
    Olsson AG
    Lakartidningen; 2011 Jun 1-14; 108(22-23):1240-3. PubMed ID: 21786498
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose statin therapy: benefits and safety in aggressive lipid lowering.
    Toth PP; Davidson MH
    J Fam Pract; 2008 May; 57(5 Suppl High-Dose):S29-36. PubMed ID: 18662521
    [No Abstract]   [Full Text] [Related]  

  • 14. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
    Schima SM; Maciejewski SR; Hilleman DE; Williams MA; Mohiuddin SM
    Expert Opin Pharmacother; 2010 Apr; 11(5):731-8. PubMed ID: 20210682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of low-density lipoprotein targets.
    Whayne TF
    Angiology; 2013 Aug; 64(6):411-6. PubMed ID: 22734087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P; Attvall S; Nilsson PM
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment with statins].
    Bogsrud MP; Reikvam Å; Retterstøl K
    Tidsskr Nor Laegeforen; 2013 Jun; 133(12-13):1316-9. PubMed ID: 23817262
    [No Abstract]   [Full Text] [Related]  

  • 18. Lipid abnormalities and cardiovascular risk in the elderly.
    Milionis HJ; Elisaf MS; Mikhailidis DP
    Curr Med Res Opin; 2008 Mar; 24(3):653-7. PubMed ID: 18218195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are we lowering LDL cholesterol sufficiently?
    Barter P; Rye KA
    Nat Clin Pract Cardiovasc Med; 2006 Jun; 3(6):290-1. PubMed ID: 16728988
    [No Abstract]   [Full Text] [Related]  

  • 20. Drugs for lipids.
    Treat Guidel Med Lett; 2011 Mar; 9(103):13-20. PubMed ID: 21350395
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.